Clinical  	Clinical  	 JJ	B-NP
roundtable  	roundtable  	 JJ	I-NP
monograph 	monograph 	 NN	I-NP
:  	:  	 :	O
Recent  	Recent  	 JJ	B-NP
advances  	advances  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
mantle  	mantle  	 JJ	B-NP
cell  	cell  	 NN	I-NP
lymphoma 	lymphoma 	 NNS	I-NP
:  	:  	 :	O
a  	a  	 DT	O
post-ASH  	post-ASH  	 JJ	B-NP
2009  	2009  	 CD	O
discussion  	discussion  	 NN	B-NP
Mantle  	Mantle  	 NNP	I-NP
cell  	cell  	 NN	I-NP
lymphoma  	lymphoma  	 NNS	I-NP
( 	( 	 -LRB-	O
MCL 	MCL 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
a  	a  	 DT	O
rare  	rare  	 JJ	O
subtype  	subtype  	 NN	B-NP
of  	of  	 IN	I-NP
non-Hodgkin  	non-Hodgkin  	 JJ	I-NP
lymphoma  	lymphoma  	 NNS	I-NP
characterized  	characterized  	 VBN	O
by  	by  	 IN	O
CD5  	CD5  	 CD	B-NP
expression  	expression  	 NN	I-NP
and  	and  	 CC	O
a  	a  	 DT	O
t 	t 	 NN	B-NP
( 	( 	 -LRB-	I-NP
11 	11 	 CD	I-NP
; 	; 	 :	O
14 	14 	 CD	O
)  	)  	 -RRB-	O
cytogenetic  	cytogenetic  	 JJ	B-NP
translocation  	translocation  	 NN	I-NP
that  	that  	 IN	O
results  	results  	 NNS	O
in  	in  	 IN	O
overexpression  	overexpression  	 NN	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
cyclin  	cyclin  	 JJ	I-NP
D1  	D1  	 CD	I-NP
gene 	gene 	 NN	I-NP
.  	.  	 .	O
Currently 	Currently 	 RB	O
,  	,  	 ,	O
there  	there  	 EX	O
is  	is  	 VBZ	O
no  	no  	 DT	O
standard  	standard  	 NN	O
of  	of  	 IN	O
care  	care  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
MCL 	MCL 	 NNP	O
,  	,  	 ,	O
and  	and  	 CC	O
patient  	patient  	 JJ	O
prognosis  	prognosis  	 NN	O
is  	is  	 VBZ	O
poor 	poor 	 JJ	O
.  	.  	 .	O
Traditional  	Traditional  	 JJ	B-NP
treatments  	treatments  	 NNS	I-NP
for  	for  	 IN	O
MCL  	MCL  	 NNP	O
rely  	rely  	 VBP	O
on  	on  	 IN	O
conventional  	conventional  	 JJ	B-NP
chemotherapy  	chemotherapy  	 JJ	I-NP
agents 	agents 	 NNS	I-NP
,  	,  	 ,	O
including  	including  	 VBG	B-NP
cyclophosphamide 	cyclophosphamide 	 NN	I-NP
,  	,  	 ,	O
doxorubicin 	doxorubicin 	 NN	B-NP
,  	,  	 ,	O
vincristine 	vincristine 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
prednisone  	prednisone  	 NNS	B-NP
( 	( 	 -LRB-	O
CHOP 	CHOP 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
addition  	addition  	 NN	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
immunotherapeutic  	immunotherapeutic  	 JJ	I-NP
agent  	agent  	 NN	I-NP
rituximab  	rituximab  	 NN	I-NP
to  	to  	 TO	O
this  	this  	 DT	O
regimen  	regimen  	 NN	O
( 	( 	 -LRB-	O
CHOP-R 	CHOP-R 	 NNP	B-NP
)  	)  	 -RRB-	O
has  	has  	 VBZ	O
helped  	helped  	 VBN	O
to  	to  	 TO	O
improve  	improve  	 VB	O
patient  	patient  	 JJ	O
response  	response  	 NN	O
to  	to  	 TO	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
These  	These  	 DT	O
treatments  	treatments  	 NNS	O
often  	often  	 RB	O
provide  	provide  	 VB	O
good  	good  	 JJ	O
initial  	initial  	 JJ	O
responses  	responses  	 NNS	O
that  	that  	 WDT	O
are  	are  	 VBP	O
difficult  	difficult  	 JJ	O
to  	to  	 TO	O
sustain 	sustain 	 VB	O
.  	.  	 .	O
Therefore 	Therefore 	 RB	O
,  	,  	 ,	O
a  	a  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
newer  	newer  	 JJR	O
agents  	agents  	 NNS	O
and  	and  	 CC	O
combinations  	combinations  	 NNS	B-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
investigated  	investigated  	 VBN	O
to  	to  	 TO	O
produce  	produce  	 VB	O
more  	more  	 RBR	O
durable  	durable  	 JJ	O
benefit 	benefit 	 NN	O
.  	.  	 .	O
Several  	Several  	 JJ	O
of  	of  	 IN	O
these  	these  	 DT	O
advances  	advances  	 NNS	O
were  	were  	 VBD	O
reported  	reported  	 VBN	O
at  	at  	 IN	O
the  	the  	 DT	O
51st  	51st  	 NNP	O
American  	American  	 NNP	O
Society  	Society  	 NNP	O
of  	of  	 IN	O
Hematology  	Hematology  	 NNP	B-NP
( 	( 	 -LRB-	O
ASH 	ASH 	 NNP	O
)  	)  	 -RRB-	O
Annual  	Annual  	 NNP	O
Meeting  	Meeting  	 NNP	O
and  	and  	 CC	O
Exposition 	Exposition 	 NNP	O
,  	,  	 ,	O
held  	held  	 VBD	O
December  	December  	 NNP	O
5-8 	5-8 	 NNP	O
,  	,  	 ,	O
2009  	2009  	 CD	O
in  	in  	 IN	O
New  	New  	 NNP	O
Orleans 	Orleans 	 NNP	O
,  	,  	 ,	O
Louisiana 	Louisiana 	 NNP	B-NP
.  	.  	 .	O
In  	In  	 IN	O
this  	this  	 DT	O
clinical  	clinical  	 JJ	B-NP
roundtable  	roundtable  	 JJ	I-NP
monograph 	monograph 	 NN	I-NP
,  	,  	 ,	O
new  	new  	 JJ	O
strategies  	strategies  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
MCL  	MCL  	 NNP	O
are  	are  	 VBP	O
discussed 	discussed 	 VBN	O
.  	.  	 .	O
Some  	Some  	 DT	O
of  	of  	 IN	O
the  	the  	 DT	O
drug  	drug  	 NN	B-NP
classes  	classes  	 NNS	I-NP
examined  	examined  	 VBD	O
here  	here  	 RB	O
are  	are  	 VBP	O
proteasome  	proteasome  	 JJ	B-NP
inhibitors 	inhibitors 	 NN	I-NP
,  	,  	 ,	O
inhibitors  	inhibitors  	 VBG	O
of  	of  	 IN	O
the  	the  	 DT	O
protein  	protein  	 NN	B-NP
mammalian  	mammalian  	 NN	I-NP
target  	target  	 NN	I-NP
of  	of  	 IN	I-NP
rapamycin  	rapamycin  	 NNS	I-NP
( 	( 	 -LRB-	O
mTOR 	mTOR 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
the  	the  	 DT	O
unique  	unique  	 JJ	O
alkylating  	alkylating  	 JJ	O
agent  	agent  	 NN	B-NP
bendamustine 	bendamustine 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
immunomodulatory  	immunomodulatory  	 JJ	B-NP
agents 	agents 	 NNS	I-NP
.  	.  	 .	O
